Afatinib + Nimotuzumab

The combination of afatinib and nimotuzumab is a dual targeting approach for epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC). Afatinib is a potent irreversible ErbB family blocker, while nimotuzumab is a humanized anti-EGFR monoclonal antibody[1][2]. This combination has been studied specifically in patients with acquired resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib or erlotinib[1]. ## Clinical Development A Phase Ib/II study evaluated this combination in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. The study determined that the recommended Phase II dose (RP2D) was afatinib 40 mg once daily plus nimotuzumab 100 mg once weekly[1][2]. In the clinical trial, 50 patients were enrolled (13 in phase Ib and 37 in phase II). The combination demonstrated an acceptable safety profile with manageable adverse events. The most common grade 3 toxicities were skin rash (7%), diarrhea (5%), acne (2%), and fatigue (2%)[1]. ## Efficacy Results The combination showed encouraging antitumor activity: - Overall response rate: 23% - Median duration of response: 4.3 months (range 0.7-16.2 months) - Median progression-free survival: 4.0 months (95% CI, 2.3-5.7 months) - Median overall survival: 11.7 months (95% CI, 9.4-14.0 months)[1] ## Scientific Rationale Preclinical studies using a mouse xenograft model showed that nimotuzumab enhanced the antitumor efficacy of afatinib, providing the scientific basis for this combination approach[2]. This dual targeting strategy aims to overcome resistance mechanisms that develop after treatment with first-generation EGFR TKIs. The combination represents an interesting approach to targeting EGFR through complementary mechanisms - afatinib's irreversible binding to the intracellular domain of EGFR and other ErbB family members, and nimotuzumab's binding to the extracellular domain of EGFR[1][2][4].